Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Equine immunoglobulin F(ab')

Yongkun Zhao1, Xuexing Zheng2, Shihua He3

  • 1Institute of Military Veterinary Medicine, Academy of Military Medical Science, Changchun 130122, China; Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Disease and Zoonoses, Yangzhou 225009, China.

International Immunopharmacology
|September 11, 2018
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Corrigendum to "A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2" [Antivir. Res. 225 (2024) 105854].

Antiviral research·2026
Same author

A Fully Human Derived Monoclonal Antibody Provides Potent Pre- and Postexposure Protection Against Rabies Virus.

Transboundary and emerging diseases·2026
Same author

<i>Poria cocos</i> Polysaccharide Fraction PCP-II Enhances Humoral and Cellular Responses to a SARS-CoV-2 RBD Subunit Vaccine in Mice.

Vaccines·2026
Same author

Engineered bispecific antibodies achieve broad and potent protection against multiple ebolavirus species.

Emerging microbes & infections·2026
Same author

IGLC3<sup>-</sup> tumor cells drive chemoresistance in colorectal cancer by polarizing SPP1<sup>+</sup> macrophages via the CD44-Wnt-BTF3 axis.

Frontiers in immunology·2026
Same author

Repurposing rosmarinic acid as an anti-colorectal cancer agent through bolstering T cell anti-tumor immunity by enhancing activation of MEK1-mediated TCR signaling.

Cancer immunology, immunotherapy : CII·2026
Same journal

Berbamine improves behavioral impairments in Huntington's disease mice models through inhibiting Src/AKT1/NFκB signaling pathway and attenuating Src-mediated mitophagy suppression.

International immunopharmacology·2026
Same journal

Macrophage autophagy in allergic diseases: Regulatory mechanisms, immune crosstalk, and therapeutic implications.

International immunopharmacology·2026
Same journal

ANXA11 recruits tumor-associated neutrophils to promote the progression of colorectal cancer.

International immunopharmacology·2026
Same journal

HO-1 alleviates lipopolysaccharide-induced acute lung injury in mice by downregulating TFE3 expression and nuclear translocation and suppressing Golgi stress response.

International immunopharmacology·2026
Same journal

Corrigendum to "Eicosapentaenoic acid attenuates hyperoxia-induced lung injury via p38 MAPK/NF-κB-mediated regulation of glycolytic reprogramming" [Int. Immunopharmacol. 168(Part 2) (2026) 115903].

International immunopharmacology·2026
Same journal

ENOX1 promotes gastric cancer progression via Snail2-mediated epithelial-mesenchymal transition and M2-type tumour-associated macrophages polarisation.

International immunopharmacology·2026
See all related articles
This summary is machine-generated.

Equine immunoglobulin F(ab)2 fragments show promise for treating Rift Valley fever virus (RVFV) infections. Passive immunotherapy with these fragments effectively neutralized RVFV in vitro and reduced mortality in vivo.

Area of Science:

  • Veterinary Virology
  • Immunology
  • Arbovirology

Background:

  • Rift Valley fever virus (RVFV) is an emerging arbovirus posing a significant threat to human and livestock health.
  • Current treatment options for RVFV infection are limited, highlighting the urgent need for effective therapeutic strategies.
  • RVFV outbreaks have been reported in Africa and the Arabian Peninsula, necessitating global preparedness.

Purpose of the Study:

  • To evaluate the therapeutic potential of equine immunoglobulin F(ab)2 fragments derived from RVFV virus-like particles (VLPs).
  • To assess the in vitro neutralization capacity and in vivo efficacy of these F(ab)2 fragments against RVFV.
  • To determine if passive immunotherapy can be a viable treatment for RVFV infections.

Main Methods:

  • Development of RVFV virus-like particles (VLPs) expressing surface glycoproteins Gn and Gc.
Keywords:
Equine immunoglobulin F(ab′)(2) fragmentsRift Valley fever virusVaccine preparationVirus-like particle

Related Experiment Videos

  • Immunization of horses with RVFV VLPs and subsequent preparation of immunoglobulin F(ab)2 fragments.
  • Characterization of F(ab)2 fragment efficacy through in vitro neutralization assays and in vivo mouse models.

    • Main Results:

    • Equine immunoglobulin F(ab)2 fragments demonstrated potent in vitro neutralization of RVFV in VeroE6 cells.
    • Passive transfer of F(ab)2 fragments significantly reduced mortality rates in RVFV-infected mice.
    • The F(ab)2 fragments exhibited protective effects against RVFV challenge.

    Conclusions:

    • Passive immunotherapy using equine immunoglobulin F(ab)2 fragments is a promising strategy for RVFV treatment.
    • These findings support the development of F(ab)2-based therapeutics for Rift Valley fever.
    • Further research into equine-derived antibodies could offer new avenues for combating RVFV disease.